Mitumomab: Difference between revisions
m Protected "Mitumomab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 33: | Line 33: | ||
{{Mousemonoclonals}} | {{Mousemonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 17:29, 9 August 2012
WikiDoc Resources for Mitumomab |
Articles |
---|
Most recent articles on Mitumomab |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Mitumomab at Clinical Trials.gov Clinical Trials on Mitumomab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Mitumomab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Mitumomab Discussion groups on Mitumomab Directions to Hospitals Treating Mitumomab Risk calculators and risk factors for Mitumomab
|
Healthcare Provider Resources |
Causes & Risk Factors for Mitumomab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Mitumomab is a mouse, anti-Idiotypic monoclonal antibody that targets GD3 ganglioside, which is over-expressed predominantly on tumours origination from the neuroectoderm.
Template:Mousemonoclonals
Template:WH
Template:WikiDoc Sources